VIR Share Price Performance
US$9.56
1.34 (16.30%)
42.3% undervalued intrinsic discount
US$16.56
Fair Value
Price US$9.56
AnalystConsensusTarget US$16.56
AnalystLowTarget US$12.00
AnalystHighTarget US$28.68
Fair ValueUS$16.56
Share Pricen/a
Vir Biotechnology, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
VIR Community Narratives
AN
Fair Value US$16.56 42.3% undervalued intrinsic discount
Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value US$12 20.3% undervalued intrinsic discount
Hepatitis Delta Headwinds And Oncology Uncertainty Will Eventually Support A Modest Recovery
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$28.68 66.7% undervalued intrinsic discount
Hepatitis Delta Franchise And T Cell Engagers Will Reshape Long Term Outlook
1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success
Key Takeaways ECLIPSE Phase III program in hepatitis delta and oncology advancements promise revenue and earnings growth through new treatments and diversified revenue streams. Restructuring to reduce expenses and strategic capital allocation enhance financial stability, ensuring long-term sustainability and support for clinical development.Read more
73
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
US$16.56
42.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
16.15%
Future PE
223.26x
Price in 2029
US$20.27
Hepatitis Delta Franchise And T Cell Engagers Will Reshape Long Term Outlook
Catalysts About Vir Biotechnology Vir Biotechnology focuses on developing treatments that harness the immune system to address serious infectious diseases and cancer. What are the underlying business or industry changes driving this perspective?Read more
6
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$28.68
66.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
16.24%
Future PE
88.85x
Price in 2029
US$35.35
Hepatitis Delta Headwinds And Oncology Uncertainty Will Eventually Support A Modest Recovery
Catalysts About Vir Biotechnology Vir Biotechnology is a clinical stage immunology company developing therapies that harness and modulate the immune system to treat serious infectious diseases and cancer. What are the underlying business or industry changes driving this perspective?Read more
23
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$12
20.3% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
16.03%
Future PE
9.52kx
Price in 2028
US$14.79
Trending Discussion
Recently Updated Narratives
AN
VIR: SOLSTICE Hepatitis Delta Data Will Drive Future Upside Repricing Potential
Fair Value: US$16.56 42.3% undervalued intrinsic discount
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Hepatitis Delta Franchise And T Cell Engagers Will Reshape Long Term Outlook
Fair Value: US$28.68 66.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Hepatitis Delta Headwinds And Oncology Uncertainty Will Eventually Support A Modest Recovery
Fair Value: US$12 20.3% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vir Biotechnology, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -2.74
- -548.38%
- -638.87%
- 0%
About VIR
- Founded
- 2016
- Employees
- 367
- CEO
- WebsiteView website
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
